Table 1.

Cell line and Patient Tumor Datasets for Gene Expression Models (GEMs) derivation and evaluation.

Cancer Type	Patient Population	Study Name	Microarray Type	No. Patients	Chemo Regimen	Treatment Course	Tumor Response*	Survival Data**	Reference
Training Sets
Mixed	(Cell lines)	NCI-60	HG-U133A	60	None	n/a	n/a	n/a	Lee et al (6)
Bladder	New York	BL-89	HG-U133A	89*	None	n/a	n/a	n/a	Wu et al (8)
Ovarian	Michigan	OV-99	HG-U133A	99	None	n/a	n/a	n/a	Hendrix et al (9)
Breast	Sweden	BR-251	HG-U133A	251	None	n/a	n/a	n/a	Miller et al (10)
Test Sets
Bladder	Japan	BL-Jap	cDNA	45	MVAC	Neoadjuvant	Down- stage (R 23, N 22)	Overall Survival	Takata et al (15)
	Denmark	BL-Den	HG-U133A	14	MVAC	No Surgery	WHO criteria (R 3, N 11)	Overall Survival	Als et al (16)
Ovarian	North Carolina, Florida	OV-NC	HG-U133A	119	Platinum	Adjuvant	Pathologic Response (R 85, N 34)	Overall Survival	Dressman et al (3)
	Georgia	OV-GA	HG-U95A	24	CT	Neoadjuvant	No	Overall Survival (S12, D 12)	Moreno et al (19)
Breast	Texas / Peru	BR-TX^	HG-U133A	133	TFAC	Neoadjuvant	Pathologic Response (R 34, N 99)	No	Hess et al (20)
	North Carolina, Taiwan	BR-Tai	HG-U95A	45	FAC	Adjuvant	No	Overall Survival (S 38, D 7)	Bild et al (21)
	Germany	BR-Ger^	DKFZ/Opern Human Oligo	100	GED	Neoadjuvant	Pathologic Response (R 24, N 76)	No	Thuerigen et al (22)

MVAC (Methotrexate, Vinblastine, Adriamycin, Cisplatin), CT (Carboplatin, Taxol), Platinum (Carboplatin or Cisplatin and additional unspecified chemotherapeutic compounds), TFAC (Taxol, 5-FU, Adriamycin, Cyclophosphamide), FAC (same as TFAC without Taxol), GED (Gemcitabine, Epirubicin, Docetaxel).

^*Defined as reported by the original authors (R: responder, N: non-responder).

^**Used absolute survival as a surrogate of clinical response if no clinical response data available (S: survivor, D: deceased).

^{^}Prospective Clinical Trial.